Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Faraday Future Intelligent Electric Financial Results
Faraday Future reported Q3 2026 revenue of $1.15 million, a significant increase from $37,000 in the prior-year period, driven primarily by its newly incubated robotics business. The company's net loss narrowed by over 95% to $9.8 million, while it successfully completed the spin-off of its robotics assets into FFR, a standalone Nasdaq-listed entity in which Faraday Future remains the controlling stockholder.
Artisan Consumer Goods, Inc. reported a net loss of $11,331 for the quarter ended September 30, 2026, an improvement from a $21,012 loss in the prior year. The company remains in a pre-revenue stage as it searches for a new manufacturer for its Within / Without Granola brand, resulting in a total stockholders' deficiency of $372,908.
Cue Biopharma reported third quarter 2026 financial results and highlighted the initiation of first-in-human dosing for CUE-401, its first autoimmune therapeutic candidate. The company also shared positive Phase 2 findings for CUE-221 in chronic spontaneous urticaria (CSU), demonstrating statistically significant hives resolution and potential differentiation from existing therapies like Xolair.
Term
Q3 2026
“We are seeing exciting momentum across our portfolio. We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy.”
Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma
“Our goal is to move beyond partial protection toward more complete, sustained protection for patients, including those with high baseline IgE who remain underserved by current therapies. In parallel, we are advancing half-life extension efforts for CUE-221, aimed at further enhancing patient convenience.”
Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma
For the nine months ended September 30, 2026, Lightstone Value Plus REIT II reported a net loss of $7.3 million on revenues of $38.1 million, compared to a net loss of $4.2 million in the prior year period. The increased loss was primarily driven by $5.5 million in impairment charges and higher property operating expenses, while the company also designated $9.4 million in assets as held for sale.
1606 CORP. reported a significant increase in net loss to $3.16 million for the nine months ended September 30, 2026, compared to $0.80 million in the prior year, primarily driven by higher interest expenses and changes in the fair value of derivative liabilities. The company's strategic focus has shifted toward power infrastructure and energy assets for AI data centers, though it currently faces substantial doubt about its ability to continue as a going concern due to a lack of revenue and a $5.85 million stockholders' deficit.
Zeo Energy Corp. reported total net revenues of $55.7 million for the nine months ended September 30, 2026, an increase from $50.8 million in the prior year period. Despite the revenue growth, the company recorded a net loss of $6.2 million for the first nine months of 2026, though this was a significant improvement from the $17.9 million net loss reported in the same period of 2025.
NextNRG, Inc. reported a significant increase in nine-month sales to $75.5 million for 2026, up from $58.8 million in 2025, though it continues to operate at a net loss of $25.6 million. The company underwent a name change from EzFill Holdings, Inc. and maintains a substantial stockholders' deficit of $33.6 million as of September 30, 2026.
Pioneer Power Solutions reported a significant decline in revenues to $14.3 million for the nine months ended September 30, 2026, compared to $22.0 million in the prior year. The company experienced a net loss of $6.6 million during this period, driven by lower sales and a $1.4 million impairment charge related to software development costs.
GridAI Technologies Corp. reported a significant increase in net loss to $19.9 million for the nine months ended September 30, 2026, driven largely by a $10.1 million goodwill impairment and rising general and administrative expenses. Total stockholders' equity declined from $24.9 million at the end of 2025 to $15.4 million as of September 30, 2026.
Aspira Women's Health Inc. reported a net loss of $1.4 million for the nine months ended September 30, 2026, a significant improvement from the $9.4 million loss in the prior year, primarily driven by a $4.5 million gain from the change in fair value of warrant liabilities. Total revenue decreased to $5.9 million from $7.0 million year-over-year, while total operating expenses were reduced from $11.1 million to $8.5 million.
Bonk, Inc. reported a net loss of $10.4 million for the nine months ended September 30, 2026, compared to a $25.5 million loss in the prior year period. Total assets decreased significantly from $41.0 million at year-end 2025 to $28.0 million, primarily due to a reduction in non-current digital assets.
Wrap Technologies reported total revenues of $4.67 million for the nine months ended September 30, 2026, a significant increase from $3.27 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $10.73 million due to increased selling, general, and administrative expenses, though its cash position improved to $12.09 million following a private placement.
Beneficient reported financial results for its fiscal 2027 second quarter ended September 30, 2026, highlighting a significant reduction in year-to-date operating expenses to $26.6 million from $95.1 million in the prior year. The company is advancing strategic initiatives to eliminate $130 million in purported debt associated with its former CEO and plans to launch AltLens, an AI-driven portfolio analytics platform.
Term
Q2 2027
“Our second quarter results for FY 2027 demonstrated that we are continuing to make progress on multiple fronts: advancing financing initiatives, executing collateral management transactions, monetizing assets, pursuing new originations and follow-on business, and reducing operating expenses. Beneficient remains focused on putting legacy matters behind it as it moves to the next phase of its development, and we believe AltLens will be an important part of that strategy.”
XBP Global reported Q3 2026 revenue of $182.8 million, a 12.6% year-over-year decline primarily due to planned client exits. Despite the revenue drop, the company achieved a record normalized EBITDA margin of 12.4% and reported its strongest bookings quarter since its 2025 merger, with $147.5 million in total contract value (TCV) bookings.
Term
Q3 2026
“In the third quarter, normalized EBITDA grew sequentially for the second consecutive quarter and normalized EBITDA margin reached 12.4%, the highest for the combined company, as our AI-first operating model continued to expand margins.”
Andrej Jonovic, Chief Executive Officer of XBP Global
“Revenue declined year-over-year largely as we anticipated, as client exits that began last year continued to run off. Commercially, this was our strongest bookings quarter since the combination in July 2025.”
Andrej Jonovic, Chief Executive Officer of XBP Global
Flyte Aviation reported record Q3 2026 aviation revenue of $1.84 million, a 145% sequential increase driven by a 129% surge in flight hours. The company is expanding its fleet with three additional jets expected to enter service in Q4 2026 and recently secured regulatory clearance to begin operations in Canada.
Term
Q3 2026
“I am delighted with the rapid ramp up of Flyte’s revenue, aircraft utilization and more. Our financial and operating results combined with increasing customer demand further validates our business strategy of providing the convenience, comfort, time efficiency and reliability of short-hop private aviation at a highly competitive price.”
Envela Corp reported Q3 2026 financial results with revenue of $43.4 million and net income of $3.9 million. Despite a revenue decline from the prior year due to lower precious metals activity, the company expanded gross margins to 29.4% and grew operating income by 11.5%.
Term
Q3 2026
“Through nine months we have earned $0.65 per diluted share, nearly double the prior-year period and already more than all of 2025. Precious metals traded well below January’s record levels, customer selling normalized and Consumer revenue stepped down from last year’s elevated base. Even so, quarterly diluted earnings per share rose 15.4 percent to $0.15, operating income grew 11.5 percent to $4.7 million and gross margin expanded to 29.4 percent of revenue on a favorable sales mix. That is the model working as designed.”
John Loftus, CEO of Envela
“Consumer segment gross margin rose to 17.5 percent from 11.5 percent a year ago as mix shifted away from wholesale, and our Commercial segment grew revenue again on steady demand for re-commerced technology assets and components. We generated $33.5 million in operating cash flow year to date, retired the Consumer segment’s bank note, repurchased 67,435 shares and ended September with $35.6 million in net cash, up from $8.2 million at year-end.”
Lument Finance Trust reported its third quarter 2026 financial results, posting a GAAP net loss of $13.5 million, or $2.57 per share. The company also reported a non-GAAP Distributable Loss of $0.7 million, or $0.13 per share, for the period ended September 30, 2026.
Metech Group Inc. reported a significant increase in net income to $1,083,316 for the nine months ended September 30, 2026, compared to $501,013 in the prior year period, driven by a 18.4% growth in revenues. The company successfully alleviated its going concern doubt due to recent profitability and financial support from significant shareholders.
Stark Novus Financial Inc. reported a net loss of $2.5 million for the quarter ended September 30, 2026, as it transitioned into insurance and wealth management services following its reorganization. The company's balance sheet shows a shift from a positive stockholders' equity of $2.6 million at the end of 2025 to a deficit of $2.3 million by September 2026.
Limitless X Holdings Inc. reported a significant decline in net revenue to $143,399 for the nine months ended September 30, 2026, compared to $802,396 in the prior year. The company incurred a net loss of $34,096,665 during this period, driven largely by a $27.8 million loss on the conversion of Preferred C to Preferred D stock and high salary expenses.
Feel The World, Inc. reported a significant turnaround for the nine months ended September 30, 2026, with net income of $2.15 million compared to a net loss of $1.91 million in the prior year period. Revenue grew to $50.69 million, driven by improved gross margins and operational efficiencies, despite an accumulated deficit of $4.28 million.
TruGolf Holdings reported a net loss of $3.98 million for the nine months ended September 30, 2026, a significant improvement from the $13.27 million loss in the prior year period. Revenue grew 16.8% to $16.13 million, while the company's stockholders' equity shifted to a deficit of $22,716 as of the end of the quarter.
Tevogen Inc. reported a net loss of $18.2 million for the nine months ended September 30, 2026, compared to $21.6 million in the prior year period. The company continues to operate with a significant stockholders' deficit of $11.3 million and relies on financing activities, including a $3.0 million loan and $3.0 million from pre-funded warrants, to fund its biotechnology and AI initiatives.
Lightstone Value Plus REIT III reported a net loss of $7.2 million for the nine months ended September 30, 2026, compared to a $3.3 million loss in the prior year, primarily driven by a $4.6 million impairment charge. Total assets decreased to $110.8 million from $117.2 million at year-end 2025, while total equity declined to $46.7 million due to the net loss and share redemptions.
Integrated Rail & Resources Inc. reported a net income of $685,749 for the nine months ended September 30, 2026, a significant recovery from a net loss of $5,562,621 in the prior year period, primarily driven by a $5.8 million gain from the change in fair value of warrant liabilities. Despite the net profit, the company maintains a stockholders' deficit of $16.2 million and notes substantial doubt about its ability to continue as a going concern as it works toward a 2028 facility in-service date.
Beneficient reported a net loss of $39.4 million for the quarter ended September 30, 2026, compared to a loss of $17.9 million in the prior year period. Total assets decreased to $227.3 million from $238.8 million at fiscal year-end, while the company's accumulated deficit grew to $2.12 billion.
Vivos Therapeutics is transitioning from a legacy dentist-focused model to a medical-provider focused sales and distribution model, highlighted by the acquisition of The Sleep Center of Nevada and a transaction with SOD Sciences. The company faces significant challenges regarding its Nasdaq listing requirements and the integration of its new business model while managing substantial indebtedness.
For the nine months ended September 30, 2026, Global Macro Trust reported a significant turnaround with a net income of $8,596,407 compared to a net loss of $3,561,629 in the prior year period. This performance was driven by $9,247,519 in total net realized and unrealized gains, primarily from futures and forward currency contracts, which offset a net investment loss of $636,505.
Super League Enterprise reported a net loss of $11.3 million for the nine months ended September 30, 2026, compared to $10.6 million in the prior year period, despite a 6% increase in revenue to $8.6 million. The company's balance sheet shows a significant decrease in cash and cash equivalents from $14.4 million at year-end 2025 to $4.4 million as of September 30, 2026.
Mangoceuticals, Inc. is a smaller reporting company and emerging growth company focused on scaling its operations and marketing its products. The filing highlights significant risks including a limited operating history, the need for additional funding, and reliance on third-party compounding pharmacies for products not approved by the FDA.